A 12-week prospective cohort enrolled 73 patients with guideline-based asthma or COPD and no speech-affecting comorbidities, ...

Deepak Bhatt, MD, MPH, MBA, discusses hot new topics reshaping care for diabetes, obesity, and cardiovascular disease. One example of this new era is the SURPASS-CVOT trial (NCT04255433), a ...

The FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor for lowering low-density lipoprotein ...

This study examines how key players in managed care drive postacute home health referrals, identifying tensions, limited ...

Facility charges exceeded professional fees in variability for 25 of 26 services, with median facility interquartile ratios 2.56 versus 1.78 for professional prices ...

Propensity-matched comparisons across 11 Kaiser Permanente Southern California service areas showed similar 30-day composite ...

A rebate-driven formulary model allegedly incentivized higher insulin list prices, affecting three PBMs controlling roughly ...

Analyses spanning 35,245 patients across 13 scenarios found comparable initiation of any systemic therapy in Medicare ...

In the second and final part of her interview with The American Journal of Managed Care ® (AJMC ®), Cherie Daly, MD, director ...

Gedatolisib is the first approved agent to inhibit class I PI3K isoforms plus both mTOR complexes, addressing a long-standing challenge in comprehensive PI3K/AKT/mTOR pathway blockade. The indication ...

Learn how myeloma experts sequence BCMA vs GPRC5D bispecifics, manage CRS with prophylactic tocilizumab, and plan for CELMoDs. In 'Bispecific Sequencing, CRS Risk, and CELMoDs: Navigating the Evolving ...

INCA033989 showed encouraging spleen, anemia, and molecular responses in mutant calreticulin myelofibrosis, suggesting ...